BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Almonertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Almonertinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04841811-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT04841811)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MD
 T-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance i
 n EGFRm+ Unresectable Stage III NSCLC (APPROACH)\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04841811
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06752408-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06752408)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Au
 molertinib Versus Osimertinib As First-line Therapy for Patients with EGFR
  Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer\nEstima
 ted primary completion: 16 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06752408
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06947811-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Almonertinib: Phase 1/2 readout est. (NCT06947811)
DESCRIPTION:Almonertinib\, phase 1/2.\nStudy: A Study of Almonertinib Combi
 ned With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS
  Mutations\nEstimated primary completion: March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06947811
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951464-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06951464)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage
  II-IIIB NSCLC\nEstimated primary completion: 5 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06951464
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503888-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Almonertinib: Phase 1/2 readout est. (NCT05503888)
DESCRIPTION:Almonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment 
 of Relapsed or Advanced Non-small Cell Lung Cancer\nEstimated primary comp
 letion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05503888
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463171-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06463171)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Can
 cer\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06463171
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800223-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT05800223)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ar
 matinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated
  Non-small Cell Lung Cancer\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/almonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05800223
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645222-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Almonertinib: Phase 1 readout est. (NCT07645222)
DESCRIPTION:Almonertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: PH
 ASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC\nEstimated primary comp
 letion: 31 October 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07645222
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624487-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Almonertinib: Phase 2 readout est. (NCT07624487)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Au
 molertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarc
 inoma\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07624487
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699952-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Almonertinib: Phase 2 readout est. (NCT07699952)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fi
 rst-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inh
 ibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-smal
 l Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human 
 Epidermal Growth Factor Receptor 2(HER2) Alterations\nEstimated primary co
 mpletion: March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07699952
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474455-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Almonertinib: Phase 1/2 readout est. (NCT06474455)
DESCRIPTION:Almonertinib\, phase 1/2.\nStudy: A Phase IB/II Clinical Study 
 of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Pati
 ents With Advanced Solid Tumors\nEstimated primary completion: June 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/almonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06474455
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873086-1984@assetmemo.bio
DTSTAMP:20261121T005636Z
DTSTART;VALUE=DATE:20301010
DTEND;VALUE=DATE:20301011
SUMMARY:Almonertinib: Phase na readout est. (NCT07873086)
DESCRIPTION:Almonertinib\, phase na\, Non-Small Cell Lung Cancer.\nStudy: M
 RD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSC
 LC\nEstimated primary completion: 10 October 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07873086
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
